NeueHealth Inc (NEUE) AI Stock Analysis

• Market Cap: $60.73M
• Dividend Yield: N/A
• Average Volume (3M): 6.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.34
• Revenue Growth: -13.83%
• EPS Growth: 87.09%
• Country: US
• Employees: 986
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Equipment & Services
• EPS (TTM): -1.68
• Shares Outstanding: 9,024,240
• 10 Day Avg. Volume: 7,166
• 30 Day Avg. Volume: 6,788
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 20.61
• Enterprise Value/Revenue: 1.41
• Enterprise Value/Gross Profit: 5.81
• Enterprise Value/Ebitda: -58.26
• 1Y Price Target: $6.50
• Price Target Upside: -3.42% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: $6.50 ▼(-3.42% Downside)

The overall stock score is primarily impacted by the company's weak financial performance, characterized by declining revenues and negative profitability. While the earnings call provided positive sentiment and strategic growth highlights, these are overshadowed by the financial instability. Technical analysis and valuation also suggest caution, with mixed signals and a negative P/E ratio.

NeueHealth Inc Business Overview & Revenue Model

Company Description

NeueHealth, Inc., a healthcare company, provides various healthcare services for health consumers, providers, and payors in the United States. It operates through two segments: NeueCare and NeueSolutions. The NeueCare segment delivers healthcare services to ACA marketplace, medicare, and medicaid through owned and affiliated clinics. It operates risk-bearing clinics under the Centrum Health, AssociatesMD, and Premier Medical Associates brand names. The company also offers integrated system care solution, such as embedded pharmacy, laboratory, radiology, and population health focused specialty services; and chronic care management, transitions of care, and referral management services. The NeueSolutions segment enables providers and medical groups to succeed in performance-based arrangements; and participates in the centers for healthcare access to medicare beneficiaries. The company was formerly known as Bright Health Group, Inc. and changed its name to NeueHealth, Inc. in January 2024. NeueHealth, Inc. was incorporated in 2015 and is headquartered in Doral, Florida.

How the Company Makes Money

NeueHealth generates revenue through multiple streams, including subscription fees from healthcare providers for access to its digital health platform, transaction fees from telehealth consultations, and licensing fees for its data analytics tools. Additionally, the company may engage in strategic partnerships with healthcare organizations, insurance companies, and technology firms to expand its service offerings and reach. These collaborations can lead to revenue-sharing agreements, further enhancing its income potential. The increasing demand for telehealth services and digital health solutions, accelerated by the COVID-19 pandemic, has significantly contributed to NeueHealth's growth and revenue generation.

NeueHealth Inc Financial Statement Overview

Summary

NeueHealth Inc is facing significant financial challenges, with declining revenues, negative profitability margins, and a weak balance sheet characterized by negative equity. Cash flow issues further exacerbate the situation, with negative growth and operational inefficiencies.

Income Statement

NeueHealth Inc has experienced declining revenue growth, with a negative growth rate of -1.86% in the TTM period. The company also shows negative profitability margins, including a net profit margin of -10.71% and an EBIT margin of -5.55%, indicating ongoing operational challenges. Despite a slight improvement in gross profit margin to 24.21% in the TTM, the overall financial health remains weak.

Balance Sheet

The balance sheet reflects significant financial instability, with negative stockholders' equity and a concerning return on equity of 14.26% in the TTM, driven by negative net income. The debt-to-equity ratio is negative due to negative equity, indicating potential solvency issues. The equity ratio is also negative, highlighting a precarious financial position.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, with a free cash flow growth rate of -25.08% in the TTM. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting income to cash. However, the free cash flow to net income ratio of 1.06 indicates some ability to cover net losses with free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	890.44M	936.66M	1.16B	751.16M	1.51B	514.89M
Gross Profit	215.55M	194.52M	164.22M	88.19M	218.88M	62.97M
EBITDA	-21.48M	-65.11M	-566.80M	-318.18M	-308.58M	-257.60M
Net Income	-95.38M	-134.68M	-1.15B	-1.46B	-1.18B	-248.44M
Balance Sheet
Total Assets	743.69M	544.38M	1.23B	4.67B	3.60B	1.81B
Cash, Cash Equivalents and Short-Term Investments	145.56M	93.17M	93.56M	217.88M	289.28M	988.30M
Total Debt	1.00M	204.61M	370.35M	350.06M	155.00M	28.42M
Total Liabilities	1.14B	930.49M	1.48B	3.73B	2.32B	2.27B
Stockholders Equity	-448.78M	-434.69M	-343.53M	719.93M	1.15B	1.18B
Cash Flow
Free Cash Flow	-74.05M	-125.55M	-2.73B	207.02M	51.65M	-63.71M
Operating Cash Flow	-69.94M	-123.22M	-2.73B	234.47M	82.06M	-57.24M
Investing Cash Flow	56.99M	186.89M	1.12B	-429.72M	-552.89M	-689.74M
Financing Cash Flow	-35.58M	-253.55M	49.91M	1.07B	1.04B	712.44M

NeueHealth Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.73
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEUE, the sentiment is Positive. The current price of 6.73 is above the 20-day moving average (MA) of 6.63, below the 50-day MA of 6.75, and above the 200-day MA of 6.59, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.56 is Neutral, neither overbought nor oversold. The STOCH value of 73.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NEUE.

NeueHealth Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CON	69 Neutral	$3.02B	20.29	18.79%	1.05%	―	―
CCLD	67 Neutral	$148.13M	―	22.69%	―	0.04%	98.87%
AVTX	60 Neutral	$118.63M	―	-90.25%	―	-45.35%	96.80%
HYPR	57 Neutral	$88.01M	―	-77.26%	―	-9.59%	8.78%
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
NEUE	49 Neutral	$60.73M	―	84.03%	―	-13.83%	87.09%
CBUS	42 Neutral	$68.36M	―	-160.72%	―	63.66%	36.72%

NeueHealth Inc Corporate Events

NeueHealth Inc Holds Annual Stockholders Meeting

On May 29, 2025, NeueHealth, Inc. held its annual meeting of stockholders where several key decisions were made. The stockholders elected ten directors to serve until the 2026 annual meeting, ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved the executive compensation for 2024 on a non-binding, advisory basis.